AbbVie's Allergan Aesthetics secured European Union approval for Boey, a botulinum toxin product positioned as rapid-onset with shorter duration than standard formulations. Boey represents a clinical differentiation play in a mature toxin market—targeting practitioners and patients seeking faster onset (potentially 24–48 hours) and predictable shorter duration (8–10 weeks vs. standard 12–14 weeks).
Regulatory
AbbVie Wins EU Approval for Boey, Short-Acting Botulinum Toxin for Frown Lines
Allergan Aesthetics gains European clearance for rapid-onset, shorter-duration toxin product.
1-YEAR MOVE
ABBV▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Boey's EU approval opens a new market segment for rapid-onset, shorter-duration toxin.
The EU approval validates the product's safety and efficacy profile and opens European revenue streams. For US practices, Boey's pathway through FDA (likely 510(k) or PMA pending) will determine competitive timing. If approved domestically, it could fragment the toxin market further, forcing practices to stock multiple products to meet patient preference for onset speed and duration. Allergan's scale and rebate infrastructure give it distribution advantage, but the product's clinical differentiation is modest—onset speed and duration are manageable variables, not transformative benefits.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.